\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Enhancing EU R&IThis monitoring report presents an overview of gender equality in EU R&I programmes, particularly in Horizon Europe. It focuses both on main indicators of equality within the programme – such as gender balance of research teams, leading positions, expert evaluations and expert groups – and then on how concretely the programme addresses the issue of gender equality in R&I, such as through requesting adoption of Gender Equality Plans, promoting gender mainstreaming in research, and addressing gender gaps in innovative entrepreneurship. (from the back cover)
1. Introduction (p.3)
2. Key indicators: women participation across the Framework Programmes (p. 8)
3. Project coordinators (p. 9)
4. Project researchers (p. 10)
5. Empowering women innovators (p. 14)
6. Gender equality plans (GEPs) as eligibility criterion (p. 15)
7. Integration of the gender dimension in R&I activities in Horizon Europe (p. 18)
8. Gender equality in European Partnerships (p. 22)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
